InpharmD · Financial Analysis Tool

The right drug, for the right patient, at the right margin.

InpharmD synthesizes the latest clinical evidence with each payer's policy and your formulary economics—so prescribers, P&T committees, and authorization teams act on one source of truth.

Live impact ·
Q2 2026 14,802 encounters
New margin captured monthly
$175K
Net contribution from optimized therapy selection & payer alignment.
Therapy · Indication
Best fit
Payer status
Δ margin
Tirzepatide Type 2 diabetes · 78mo F
Mounjaro 7.5mg
PA approved
+$1,284
Adalimumab Rheumatoid arthritis · 54mo M
Yusimry
Preferred
+$3,910
Apixaban A-fib · 67mo F
Eliquis 5mg
Step therapy
+$412
Pembrolizumab NSCLC · 71mo M
Keytruda
Re-route
−$148
Trusted by leading health systems
/ The problem

Four forces are reshaping pharmacy decisions—simultaneously.

No team can keep pace with all of them by hand. InpharmD watches every signal, every day, across every drug class.

Expanding therapy landscape

New drugs, new indications, and new generic and biosimilar entrants launch every quarter—each with its own evidence and economics.

Evolving clinical evidence

Guidelines, label updates, and head-to-head trial data are revised constantly—what was first-line last quarter may not be today.

Shifting payer reimbursement

Step-therapy rules, prior-auth criteria, and contract terms change throughout the year across hundreds of plans.

Volatile drug pricing

WAC, ASP, 340B, and rebate dynamics swing margin per encounter—often without notice and across every therapeutic class.

/ The solution

One platform across every drug class.

— evidence + policy + economics
01 — Real-time decision support

Surface the best therapy for every patient.

Match clinical evidence to insurance, formulary, and procurement in seconds.

02 — Streamlined authorization

Know the covered product instantly.

Cut prior-auth friction with payer-specific routing built into the workflow.

03 — Maximized financial opportunity

No noise. Only viable therapies.

Skip notifications for non-covered products and protect prescriber attention.

04 — Improved payer-policy management

See every policy, in plain view.

Lift reimbursement on any therapy with full transparency into payer rules.